Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Perphenazine

FDA-approved product (tablet, oral), marketed as Perphenazine, Trilafon.

Registered studies
34
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Perphenazine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Nausea and vomiting
  • Psychosis
  • Schizophrenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Phenothiazines with piperazine structure
FDA pharmacologic class
Phenothiazine FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA37.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli37.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae15.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis66.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

34registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Perphenazine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Perphenazine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Positron Emission Tomography (PET) Study to Assess the Degree of Dopamine-2 (D2) Receptor Occupancy in the Human Brain After Single Doses of BL-1020 or Perphenazine in Healthy Male Subjects Using [11C]Raclopride as PET Tracer

    NCT00480246 · start 2007-05

    Registered record
    Registry ID
    NCT00480246
    Conditions
    Healthy
    Interventions
    BL 1020; Perphenazine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-05
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionBL 1020; Perphenazine
    PhasePhase 1
    Registry statusCompleted

  • Antipsychotic Polypharmacy in Schizophrenia

    NCT00493233 · start 2006-11

    Registered record
    Registry ID
    NCT00493233
    Conditions
    Schizophrenia
    Interventions
    2 antipsychotic medications (combinations of olanzapine, risperidone, clozapine, seroquel, haldol, perphenazine); main antipsychotic medication and placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-11
    Completion
    Not recorded
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Intervention2 antipsychotic medications (combinations of olanzapine, risperidone, clozapine, seroquel, haldol, perphenazine); main antipsychotic medication and placebo
    PhaseNot applicable
    Registry statusCompleted

  • CATIE- Schizophrenia Trial

    NCT00014001 · start 2000-12

    Registered record
    Registry ID
    NCT00014001
    Conditions
    Schizophrenia
    Interventions
    perphenazine; olanzapine; quetiapine; risperidone; ziprasidone; clozapine; fluphenazine decanoate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2000-12
    Completion
    2004-12
    Enrolment
    1,600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventionperphenazine; olanzapine; quetiapine; risperidone +3 more
    PhasePhase 4
    Registry statusCompleted

  • Serotonergic Pharmacotherapy for Agitation of Dementia

    NCT00009204 · start 1995-09

    Registered record
    Registry ID
    NCT00009204
    Conditions
    Dementia; Alzheimer Disease; Dementia, Vascular
    Interventions
    Citalopram [Celexa]; Perphenazine [Trilafon]
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1995-09
    Completion
    2002-04
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDementia; Alzheimer Disease; Dementia, Vascular
    InterventionCitalopram [Celexa]; Perphenazine [Trilafon]
    PhasePhase 3
    Registry statusCompleted